This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
This event has left the current brief. The summary below describes the stored record; open the original sources for current conditions.
Roivant says its immune drug succeeded in trials for non-infectious uveitis, an inflammatory eye disease. The report does not specify the trial phase, results in detail or whether the drug has been approved for this use.
HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections
If further development and any required review support its use, the drug could become a treatment option for people with non-infectious uveitis, including in the United States. The article does not describe trial size, safety findings or a timeline for availability.